_id
691b08303c536f8df2318959
Ticker
AB.PA
Name
AB Science S.A
Exchange
PA
Address
3, Avenue George V, Paris, France, 75008
Country
France
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Currency
EUR
Website
https://www.ab-science.com
Description
AB Science S.A., a clinical-stage company, engages in the research, design, development, and marketing of drugs to address pathologies affecting the peripheral and central nervous system, inflammatory diseases, and cancers in France. The company's lead drug candidate is masitinib, a selective protein kinase inhibitor that targets mast cells and microglia in Phase 3 trial for the treatment of amyotrophic lateral sclerosis, progressive forms of multiple sclerosis, Alzheimer's disease, and indolent systemic mastocytosis, as well as in Phase 2 trial for mast cell activation syndrome and sickle cell disease. It also develops AB8939, a microtubule destabilizer in Phase 1 trial for the treatment of acute myeloid leukemia; and AB12319 in preclinical trial to treat sarcoma and solid tumors. In addition, the company markets its masitinib under the Masivet brand for the treatment of mast cell tumors in dogs in Europe. AB Science S.A. was incorporated in 2001 and is headquartered in Paris, France.
Last Close
1.366
Volume
246415
Current Price
1.4
Change
3.5139092240117
Last Updated
2025-12-30T12:32:12.713Z
Image
https://logo.clearbit.com/www.ab-science.com
Ipo Date
-
Market Cap
90408432
Next Dividend Date
-
Dividend Frequency
-
Dividend Rate
-
Dividend Yield
0
Sentiment
-
Sentiment Sources
0
Rating
4
Strong Buy
0
Buy
2
Hold
0
Sell
0
Strong Sell
0
Current Quarter
2025-06-30
Revenue
515000
Cost Of Revenue
364000
Gross Profit
151000
Operating Expenses
2879000
Operating Income
-2728000
Interest Expense
728000
Pretax Income
-5177000
Net Income
-5177000
Eps
-0.0887545118948447
Dividends Per Share
-
Shares Outstanding
66184793
Income Tax Expense
-1053000
EBITDA
-2526000
Operating Margin
-529.7087378640776
Total Other Income Expense Net
-2449000
Cash
5034000
Short Term Investments
-
Receivables
196000
Inventories
36000
Total Current Assets
12317000
Property Plant Equipment
1092000
Total Assets
21217000
Payables
9557000
Short Term Debt
2900000
Long Term Debt
-
Total Liabilities
48540000
Equity
-27323000
Bs_currency_symbol
-
Depreciation
272000
Change In Working Capital
-1322000
Cash From Operations
-4082000
Capital Expenditures
139000
Cash From Investing
-132000
Cash From Financing
1260000
Net Change In Cash
-2953000
Cf_currency_symbol
-
PE
-
PB
-2.9887347875416315
ROE
18.947406946528567
ROA
-24.400245086487253
FCF
-4221000
Fcf Percent
-8.196116504854368
Piotroski FScore
1
Health Score
30
Deep Value Investing Score
0.5
Defensive Investing Score
6
Dividend Investing Score
1.5
Economic Moat Investing Score
5.3
Garp Investing Score
2
Growth Investing Score
1.5
Momentum Investing Score
4
Net Net Investing Score
0.5
Quality Investing Score
1.5
Value Investing Score
2
Quarters > 0 > quarter
2025-06-30
Quarters > 0 > income Statement > revenue
515000
Quarters > 0 > income Statement > cost Of Revenue
364000
Quarters > 0 > income Statement > gross Profit
151000
Quarters > 0 > income Statement > operating Expenses
2879000
Quarters > 0 > income Statement > operating Income
-2728000
Quarters > 0 > income Statement > interest Expense
728000
Quarters > 0 > income Statement > pretax Income
-5177000
Quarters > 0 > income Statement > net Income
-5177000
Quarters > 0 > income Statement > eps
-0.0887545118948447
Quarters > 0 > income Statement > dividends Per Share
-
Quarters > 0 > income Statement > shares Outstanding
58329429
Quarters > 0 > income Statement > income Tax Expense
-1053000
Quarters > 0 > income Statement > EBITDA
-2526000
Quarters > 0 > income Statement > operating Margin
-529.7087378640776
Quarters > 0 > income Statement > total Other Income Expense Net
-2449000
Quarters > 0 > income Statement > currency_symbol
-
Quarters > 0 > balance Sheet > cash
5034000
Quarters > 0 > balance Sheet > short Term Investments
-
Quarters > 0 > balance Sheet > receivables
196000
Quarters > 0 > balance Sheet > inventories
36000
Quarters > 0 > balance Sheet > total Current Assets
12317000
Quarters > 0 > balance Sheet > property Plant Equipment
1092000
Quarters > 0 > balance Sheet > total Assets
21217000
Quarters > 0 > balance Sheet > payables
9557000
Quarters > 0 > balance Sheet > short Term Debt
2900000
Quarters > 0 > balance Sheet > long Term Debt
-
Quarters > 0 > balance Sheet > total Liabilities
48540000
Quarters > 0 > balance Sheet > equity
-27323000
Quarters > 0 > balance Sheet > currency_symbol
-
Quarters > 0 > cash Flow > net Income
-5177000
Quarters > 0 > cash Flow > depreciation
272000
Quarters > 0 > cash Flow > change In Working Capital
-1322000
Quarters > 0 > cash Flow > cash From Operations
-4082000
Quarters > 0 > cash Flow > capital Expenditures
139000
Quarters > 0 > cash Flow > cash From Investing
-132000
Quarters > 0 > cash Flow > cash From Financing
1260000
Quarters > 0 > cash Flow > net Change In Cash
-2953000
Quarters > 0 > cash Flow > currency_symbol
-
Quarters > 0 > ratios > PE
-0.0887545118948447
Quarters > 0 > ratios > PB
-2.9887347875416315
Quarters > 0 > ratios > ROE
18.947406946528567
Quarters > 0 > ratios > ROA
-24.400245086487253
Quarters > 0 > ratios > FCF
-4221000
Quarters > 0 > ratios > Piotroski FScore
1
Quarters > 0 > ratios > fcf Percent
-8.196116504854368
Quarters > 0 > health Score
30
Quarters > 1 > quarter
2024-12-31
Quarters > 1 > income Statement > revenue
512000
Quarters > 1 > income Statement > cost Of Revenue
-468000
Quarters > 1 > income Statement > gross Profit
980000
Quarters > 1 > income Statement > operating Expenses
2744000
Quarters > 1 > income Statement > operating Income
-2501000
Quarters > 1 > income Statement > interest Expense
596000
Quarters > 1 > income Statement > pretax Income
-3362000
Quarters > 1 > income Statement > net Income
-3362000
Quarters > 1 > income Statement > eps
-0.06376267690966088
Quarters > 1 > income Statement > dividends Per Share
-
Quarters > 1 > income Statement > shares Outstanding
52726770
Quarters > 1 > income Statement > income Tax Expense
-1313000
Quarters > 1 > income Statement > EBITDA
-1942000
Quarters > 1 > income Statement > operating Margin
-488.4765625
Quarters > 1 > income Statement > total Other Income Expense Net
-861000
Quarters > 1 > income Statement > currency_symbol
EUR
Quarters > 1 > balance Sheet > cash
7987000
Quarters > 1 > balance Sheet > short Term Investments
0
Quarters > 1 > balance Sheet > receivables
827000
Quarters > 1 > balance Sheet > inventories
184000
Quarters > 1 > balance Sheet > total Current Assets
14524000
Quarters > 1 > balance Sheet > property Plant Equipment
899000
Quarters > 1 > balance Sheet > total Assets
23175000
Quarters > 1 > balance Sheet > payables
5997000
Quarters > 1 > balance Sheet > short Term Debt
3924000
Quarters > 1 > balance Sheet > long Term Debt
14008000
Quarters > 1 > balance Sheet > total Liabilities
46929000
Quarters > 1 > balance Sheet > equity
-23754000
Quarters > 1 > balance Sheet > currency_symbol
EUR
Quarters > 1 > cash Flow > net Income
-3362000
Quarters > 1 > cash Flow > depreciation
667000
Quarters > 1 > cash Flow > change In Working Capital
-621000
Quarters > 1 > cash Flow > cash From Operations
-2796000
Quarters > 1 > cash Flow > capital Expenditures
64000
Quarters > 1 > cash Flow > cash From Investing
-57000
Quarters > 1 > cash Flow > cash From Financing
1707000
Quarters > 1 > cash Flow > net Change In Cash
-1141000
Quarters > 1 > cash Flow > currency_symbol
EUR
Quarters > 1 > ratios > PE
-0.06376267690966088
Quarters > 1 > ratios > PB
-3.1075809547865623
Quarters > 1 > ratios > ROE
14.153405742190788
Quarters > 1 > ratios > ROA
-14.507011866235167
Quarters > 1 > ratios > FCF
-2860000
Quarters > 1 > ratios > Piotroski FScore
1
Quarters > 1 > ratios > fcf Percent
-5.5859375
Quarters > 1 > health Score
26
Quarters > 2 > quarter
2024-06-30
Quarters > 2 > income Statement > revenue
560000
Quarters > 2 > income Statement > cost Of Revenue
-445000
Quarters > 2 > income Statement > gross Profit
268000
Quarters > 2 > income Statement > operating Expenses
4587000
Quarters > 2 > income Statement > operating Income
-4591000
Quarters > 2 > income Statement > interest Expense
634000
Quarters > 2 > income Statement > pretax Income
-5478000
Quarters > 2 > income Statement > net Income
-4469000
Quarters > 2 > income Statement > eps
-0.08646347961777763
Quarters > 2 > income Statement > dividends Per Share
-
Quarters > 2 > income Statement > shares Outstanding
51686562
Quarters > 2 > income Statement > income Tax Expense
-1009000
Quarters > 2 > income Statement > EBITDA
-4645000
Quarters > 2 > income Statement > operating Margin
-819.8214285714287
Quarters > 2 > income Statement > total Other Income Expense Net
-887000
Quarters > 2 > income Statement > currency_symbol
EUR
Quarters > 2 > balance Sheet > cash
9128000
Quarters > 2 > balance Sheet > short Term Investments
0
Quarters > 2 > balance Sheet > receivables
63000
Quarters > 2 > balance Sheet > inventories
393000
Quarters > 2 > balance Sheet > total Current Assets
14396000
Quarters > 2 > balance Sheet > property Plant Equipment
1032000
Quarters > 2 > balance Sheet > total Assets
22982000
Quarters > 2 > balance Sheet > payables
10584000
Quarters > 2 > balance Sheet > short Term Debt
2100000
Quarters > 2 > balance Sheet > long Term Debt
16215000
Quarters > 2 > balance Sheet > total Liabilities
47581000
Quarters > 2 > balance Sheet > equity
-24599000
Quarters > 2 > balance Sheet > currency_symbol
EUR
Quarters > 2 > cash Flow > net Income
-4469000
Quarters > 2 > cash Flow > depreciation
199000
Quarters > 2 > cash Flow > change In Working Capital
6184000
Quarters > 2 > cash Flow > cash From Operations
3321000
Quarters > 2 > cash Flow > capital Expenditures
91000
Quarters > 2 > cash Flow > cash From Investing
-79000
Quarters > 2 > cash Flow > cash From Financing
-175000
Quarters > 2 > cash Flow > net Change In Cash
3062000
Quarters > 2 > cash Flow > currency_symbol
EUR
Quarters > 2 > ratios > PE
-0.08646347961777763
Quarters > 2 > ratios > PB
-2.9416312370421562
Quarters > 2 > ratios > ROE
18.167405179072322
Quarters > 2 > ratios > ROA
-19.44565311983291
Quarters > 2 > ratios > FCF
3230000
Quarters > 2 > ratios > Piotroski FScore
2
Quarters > 2 > ratios > fcf Percent
5.767857142857143
Quarters > 2 > health Score
48
Quarters > 3 > quarter
2023-12-31
Quarters > 3 > income Statement > revenue
522000
Quarters > 3 > income Statement > cost Of Revenue
164000
Quarters > 3 > income Statement > gross Profit
358000
Quarters > 3 > income Statement > operating Expenses
4937000
Quarters > 3 > income Statement > operating Income
-4579000
Quarters > 3 > income Statement > interest Expense
1278000
Quarters > 3 > income Statement > pretax Income
-1566000
Quarters > 3 > income Statement > net Income
-1574000
Quarters > 3 > income Statement > eps
-0.030795295551001304
Quarters > 3 > income Statement > dividends Per Share
-
Quarters > 3 > income Statement > shares Outstanding
51111703
Quarters > 3 > income Statement > income Tax Expense
8000
Quarters > 3 > income Statement > EBITDA
-5073000
Quarters > 3 > income Statement > operating Margin
-877.2030651340996
Quarters > 3 > income Statement > total Other Income Expense Net
3013000
Quarters > 3 > income Statement > currency_symbol
EUR
Quarters > 3 > balance Sheet > cash
6066000
Quarters > 3 > balance Sheet > short Term Investments
-
Quarters > 3 > balance Sheet > receivables
236000
Quarters > 3 > balance Sheet > inventories
336000
Quarters > 3 > balance Sheet > total Current Assets
19390000
Quarters > 3 > balance Sheet > property Plant Equipment
782000
Quarters > 3 > balance Sheet > total Assets
25499000
Quarters > 3 > balance Sheet > payables
11075000
Quarters > 3 > balance Sheet > short Term Debt
2118000
Quarters > 3 > balance Sheet > long Term Debt
16606000
Quarters > 3 > balance Sheet > total Liabilities
46508000
Quarters > 3 > balance Sheet > equity
-21010000
Quarters > 3 > balance Sheet > currency_symbol
EUR
Quarters > 3 > cash Flow > net Income
-1574000
Quarters > 3 > cash Flow > depreciation
-323000
Quarters > 3 > cash Flow > change In Working Capital
-2103998
Quarters > 3 > cash Flow > cash From Operations
-7563000
Quarters > 3 > cash Flow > capital Expenditures
160000
Quarters > 3 > cash Flow > cash From Investing
-369000
Quarters > 3 > cash Flow > cash From Financing
-792000
Quarters > 3 > cash Flow > net Change In Cash
-8720000
Quarters > 3 > cash Flow > currency_symbol
EUR
Quarters > 3 > ratios > PE
-0.030795295551001304
Quarters > 3 > ratios > PB
-3.405825045216563
Quarters > 3 > ratios > ROE
7.49167063303189
Quarters > 3 > ratios > ROA
-6.17279108984666
Quarters > 3 > ratios > FCF
-7723000
Quarters > 3 > ratios > Piotroski FScore
0
Quarters > 3 > ratios > fcf Percent
-14.795019157088122
Quarters > 3 > health Score
20
Annuals > 0 > quarter
2024-12-31
Annuals > 0 > income Statement > revenue
1072000
Annuals > 0 > income Statement > cost Of Revenue
-176000
Annuals > 0 > income Statement > gross Profit
1248000
Annuals > 0 > income Statement > operating Expenses
7331000
Annuals > 0 > income Statement > operating Income
-6083000
Annuals > 0 > income Statement > interest Expense
1230000
Annuals > 0 > income Statement > pretax Income
-7832000
Annuals > 0 > income Statement > net Income
-7831000
Annuals > 0 > income Statement > eps
-0.1500000019154642
Annuals > 0 > income Statement > dividends Per Share
-
Annuals > 0 > income Statement > shares Outstanding
52206666
Annuals > 0 > income Statement > income Tax Expense
-2322000
Annuals > 0 > income Statement > EBITDA
-4917000
Annuals > 0 > income Statement > operating Margin
-567.4440298507463
Annuals > 0 > income Statement > total Other Income Expense Net
-1749000
Annuals > 0 > income Statement > currency_symbol
EUR
Annuals > 0 > balance Sheet > cash
7987000
Annuals > 0 > balance Sheet > short Term Investments
0
Annuals > 0 > balance Sheet > receivables
827000
Annuals > 0 > balance Sheet > inventories
184000
Annuals > 0 > balance Sheet > total Current Assets
14524000
Annuals > 0 > balance Sheet > property Plant Equipment
899000
Annuals > 0 > balance Sheet > total Assets
23175000
Annuals > 0 > balance Sheet > payables
5997000
Annuals > 0 > balance Sheet > short Term Debt
3924000
Annuals > 0 > balance Sheet > long Term Debt
14008000
Annuals > 0 > balance Sheet > total Liabilities
46929000
Annuals > 0 > balance Sheet > equity
-23754000
Annuals > 0 > balance Sheet > currency_symbol
EUR
Annuals > 0 > cash Flow > net Income
-7831000
Annuals > 0 > cash Flow > depreciation
667000
Annuals > 0 > cash Flow > change In Working Capital
6054000
Annuals > 0 > cash Flow > cash From Operations
525000
Annuals > 0 > cash Flow > capital Expenditures
155000
Annuals > 0 > cash Flow > cash From Investing
-136000
Annuals > 0 > cash Flow > cash From Financing
1532000
Annuals > 0 > cash Flow > net Change In Cash
1921000
Annuals > 0 > cash Flow > currency_symbol
EUR
Annuals > 0 > ratios > PE
-0.1500000019154642
Annuals > 0 > ratios > PB
-3.050553692346552
Annuals > 0 > ratios > ROE
32.96707922876147
Annuals > 0 > ratios > ROA
-33.79072276159655
Annuals > 0 > ratios > FCF
370000
Annuals > 0 > ratios > Piotroski FScore
2
Annuals > 0 > ratios > fcf Percent
0.3451492537313433
Annuals > 0 > health Score
50
Annuals > 1 > quarter
2023-12-31
Annuals > 1 > income Statement > revenue
970000
Annuals > 1 > income Statement > cost Of Revenue
383000
Annuals > 1 > income Statement > gross Profit
587000
Annuals > 1 > income Statement > operating Expenses
14016000
Annuals > 1 > income Statement > operating Income
-13429000
Annuals > 1 > income Statement > interest Expense
3960000
Annuals > 1 > income Statement > pretax Income
-11985000
Annuals > 1 > income Statement > net Income
-10048000
Annuals > 1 > income Statement > eps
-0.20231590093648624
Annuals > 1 > income Statement > dividends Per Share
-
Annuals > 1 > income Statement > shares Outstanding
49664905
Annuals > 1 > income Statement > income Tax Expense
-1937000
Annuals > 1 > income Statement > EBITDA
-12797000
Annuals > 1 > income Statement > operating Margin
-1384.4329896907218
Annuals > 1 > income Statement > total Other Income Expense Net
1444000
Annuals > 1 > income Statement > currency_symbol
EUR
Annuals > 1 > balance Sheet > cash
6066000
Annuals > 1 > balance Sheet > short Term Investments
-
Annuals > 1 > balance Sheet > receivables
236000
Annuals > 1 > balance Sheet > inventories
336000
Annuals > 1 > balance Sheet > total Current Assets
19390000
Annuals > 1 > balance Sheet > property Plant Equipment
785000
Annuals > 1 > balance Sheet > total Assets
25499000
Annuals > 1 > balance Sheet > payables
11075000
Annuals > 1 > balance Sheet > short Term Debt
2113000
Annuals > 1 > balance Sheet > long Term Debt
16606000
Annuals > 1 > balance Sheet > total Liabilities
46509000
Annuals > 1 > balance Sheet > equity
-21010000
Annuals > 1 > balance Sheet > currency_symbol
EUR
Annuals > 1 > cash Flow > net Income
-10048000
Annuals > 1 > cash Flow > depreciation
2271000
Annuals > 1 > cash Flow > change In Working Capital
-4423000
Annuals > 1 > cash Flow > cash From Operations
-16871000
Annuals > 1 > cash Flow > capital Expenditures
345000
Annuals > 1 > cash Flow > cash From Investing
-614000
Annuals > 1 > cash Flow > cash From Financing
16274000
Annuals > 1 > cash Flow > net Change In Cash
-1203000
Annuals > 1 > cash Flow > currency_symbol
EUR
Annuals > 1 > ratios > PE
-0.20231590093648624
Annuals > 1 > ratios > PB
-3.281051315564017
Annuals > 1 > ratios > ROE
47.824845311756306
Annuals > 1 > ratios > ROA
-39.40546688105416
Annuals > 1 > ratios > FCF
-17216000
Annuals > 1 > ratios > Piotroski FScore
1
Annuals > 1 > ratios > fcf Percent
-17.748453608247424
Annuals > 1 > health Score
31
Annuals > 2 > quarter
2022-12-31
Annuals > 2 > income Statement > revenue
958000
Annuals > 2 > income Statement > cost Of Revenue
31000
Annuals > 2 > income Statement > gross Profit
927000
Annuals > 2 > income Statement > operating Expenses
16865000
Annuals > 2 > income Statement > operating Income
-15938000
Annuals > 2 > income Statement > interest Expense
3406000
Annuals > 2 > income Statement > pretax Income
-13611000
Annuals > 2 > income Statement > net Income
-13615000
Annuals > 2 > income Statement > eps
-0.28882652065147807
Annuals > 2 > income Statement > dividends Per Share
-
Annuals > 2 > income Statement > shares Outstanding
47139023
Annuals > 2 > income Statement > income Tax Expense
4000
Annuals > 2 > income Statement > EBITDA
-13408000
Annuals > 2 > income Statement > operating Margin
-1663.6743215031315
Annuals > 2 > income Statement > total Other Income Expense Net
2326000
Annuals > 2 > income Statement > currency_symbol
EUR
Annuals > 2 > balance Sheet > cash
7269000
Annuals > 2 > balance Sheet > short Term Investments
0
Annuals > 2 > balance Sheet > receivables
12517000
Annuals > 2 > balance Sheet > inventories
456000
Annuals > 2 > balance Sheet > total Current Assets
20872000
Annuals > 2 > balance Sheet > property Plant Equipment
1265000
Annuals > 2 > balance Sheet > total Assets
23841000
Annuals > 2 > balance Sheet > payables
7362000
Annuals > 2 > balance Sheet > short Term Debt
4664000
Annuals > 2 > balance Sheet > long Term Debt
18596000
Annuals > 2 > balance Sheet > total Liabilities
59511000
Annuals > 2 > balance Sheet > equity
-35670000
Annuals > 2 > balance Sheet > currency_symbol
EUR
Annuals > 2 > cash Flow > net Income
-13615000
Annuals > 2 > cash Flow > depreciation
-81000
Annuals > 2 > cash Flow > change In Working Capital
-2832000
Annuals > 2 > cash Flow > cash From Operations
-17471000
Annuals > 2 > cash Flow > capital Expenditures
644000
Annuals > 2 > cash Flow > cash From Investing
-360000
Annuals > 2 > cash Flow > cash From Financing
16391000
Annuals > 2 > cash Flow > net Change In Cash
-1452000
Annuals > 2 > cash Flow > currency_symbol
EUR
Annuals > 2 > ratios > PE
-0.28882652065147807
Annuals > 2 > ratios > PB
-1.834285503896832
Annuals > 2 > ratios > ROE
38.16932996916176
Annuals > 2 > ratios > ROA
-57.10750387987081
Annuals > 2 > ratios > FCF
-18115000
Annuals > 2 > ratios > Piotroski FScore
1
Annuals > 2 > ratios > fcf Percent
-18.90918580375783
Annuals > 2 > health Score
31
Annuals > 3 > quarter
2021-12-31
Annuals > 3 > income Statement > revenue
1607000
Annuals > 3 > income Statement > cost Of Revenue
111000
Annuals > 3 > income Statement > gross Profit
1496000
Annuals > 3 > income Statement > operating Expenses
15304000
Annuals > 3 > income Statement > operating Income
-13808000
Annuals > 3 > income Statement > interest Expense
56000
Annuals > 3 > income Statement > pretax Income
-14427000
Annuals > 3 > income Statement > net Income
-14463000
Annuals > 3 > income Statement > eps
-0.3043506166240713
Annuals > 3 > income Statement > dividends Per Share
-
Annuals > 3 > income Statement > shares Outstanding
47520850
Annuals > 3 > income Statement > income Tax Expense
36000
Annuals > 3 > income Statement > EBITDA
-17356000
Annuals > 3 > income Statement > operating Margin
-859.2408214063472
Annuals > 3 > income Statement > total Other Income Expense Net
-619000
Annuals > 3 > income Statement > currency_symbol
EUR
Annuals > 3 > balance Sheet > cash
8721000
Annuals > 3 > balance Sheet > short Term Investments
0
Annuals > 3 > balance Sheet > receivables
8355000
Annuals > 3 > balance Sheet > inventories
141000
Annuals > 3 > balance Sheet > total Current Assets
18187000
Annuals > 3 > balance Sheet > property Plant Equipment
1590000
Annuals > 3 > balance Sheet > total Assets
21271000
Annuals > 3 > balance Sheet > payables
11368000
Annuals > 3 > balance Sheet > short Term Debt
629000
Annuals > 3 > balance Sheet > long Term Debt
6688000
Annuals > 3 > balance Sheet > total Liabilities
44469000
Annuals > 3 > balance Sheet > equity
-23198000
Annuals > 3 > balance Sheet > currency_symbol
EUR
Annuals > 3 > cash Flow > net Income
-14463000
Annuals > 3 > cash Flow > depreciation
1731000
Annuals > 3 > cash Flow > change In Working Capital
-5556000
Annuals > 3 > cash Flow > cash From Operations
-17178000
Annuals > 3 > cash Flow > capital Expenditures
564000
Annuals > 3 > cash Flow > cash From Investing
-590000
Annuals > 3 > cash Flow > cash From Financing
5844000
Annuals > 3 > cash Flow > net Change In Cash
-11939000
Annuals > 3 > cash Flow > currency_symbol
EUR
Annuals > 3 > ratios > PE
-0.3043506166240713
Annuals > 3 > ratios > PB
-2.8433028623157166
Annuals > 3 > ratios > ROE
62.34589188723165
Annuals > 3 > ratios > ROA
-67.99398241737576
Annuals > 3 > ratios > FCF
-17742000
Annuals > 3 > ratios > Piotroski FScore
1
Annuals > 3 > ratios > fcf Percent
-11.040448039825762
Annuals > 3 > health Score
31
Valuation > metrics > PE
-0.0887545118948447
Valuation > metrics > PB
-2.9887347875416315
Valuation > final Score
50
Valuation > verdict
Fair
Profitability > metrics > ROE
18.947406946528567
Profitability > metrics > ROA
-42.03133880003247
Profitability > metrics > Net Margin
-10.05242718446602
Profitability > final Score
38
Profitability > verdict
Weak
Risk > metrics > Interest Coverage
-3.7472527472527473
Risk > final Score
15
Risk > verdict
High
Liquidity > metrics > Current Ratio
0.9887613390061812
Liquidity > metrics > Quick Ratio
0.9858713976077708
Liquidity > final Score
59
Liquidity > verdict
Weak
Prev Valuations > 0
50
Prev Valuations > 1
50
Prev Valuations > 2
50
Prev Profitabilities > 0
28
Prev Profitabilities > 1
36
Prev Profitabilities > 2
15
Prev Risks > 0
13
Prev Risks > 1
1
Prev Risks > 2
16
Prev Liquidities > 0
87
Prev Liquidities > 1
78
Prev Liquidities > 2
87
Updated At
2026-01-20T23:08:25.044Z
Earnings History > 0 > period
2026-03-31
Earnings History > 0 > report Date
2026-05-11
Earnings History > 0 > date
2026-03-31
Earnings History > 0 > before After Market
BeforeMarket
Earnings History > 0 > currency
-
Earnings History > 0 > eps Actual
-
Earnings History > 0 > eps Estimate
-
Earnings History > 0 > eps Difference
0
Earnings History > 0 > surprise Percent
-
Earnings History > 1 > period
2017-12-31
Earnings History > 1 > report Date
2017-12-31
Earnings History > 1 > date
2017-12-31
Earnings History > 1 > before After Market
-
Earnings History > 1 > currency
EUR
Earnings History > 1 > eps Actual
-0.39
Earnings History > 1 > eps Estimate
-
Earnings History > 1 > eps Difference
0
Earnings History > 1 > surprise Percent
-
AB Science S.A., a clinical-stage company, engages in the research, design, development, and marketing of drugs to address pathologies affecting the peripheral and central nervous system, inflammatory diseases, and cancers in France. The company's lead drug candidate is masitinib, a selective protein kinase inhibitor that targets mast cells and microglia in Phase 3 trial for the treatment of amyotrophic lateral sclerosis, progressive forms of multiple sclerosis, Alzheimer's disease, and indolent systemic mastocytosis, as well as in Phase 2 trial for mast cell activation syndrome and sickle cell disease. It also develops AB8939, a microtubule destabilizer in Phase 1 trial for the treatment of acute myeloid leukemia; and AB12319 in preclinical trial to treat sarcoma and solid tumors. In addition, the company markets its masitinib under the Masivet brand for the treatment of mast cell tumors in dogs in Europe. AB Science S.A. was incorporated in 2001 and is headquartered in Paris, France.
Stock Price
€0.00
increase compared to yesterday.
Dividend
Frequency:
Rate:
N/ANext Payout:
N/ADICK'S Sporting Goods, Inc. $DKS Shares Sold by Nordea Investment Management AB - MarketBeat
1/15/2026
DICK'S Sporting Goods, Inc. $DKS Shares Sold by Nordea Investment Management AB MarketBeat
Read more →AB Science announces the initiation of coverage of its stock by Maxim Group with a target price of EUR 4.0 per share Yahoo Finance UK
Read more →Showing 2 of 10
(Last Updated 2025-06-30)
Rating:
BUY
$
Analyst Picks
Strong Buy
0
Buy
2
Hold
0
Sell
0
Strong Sell
0
(Last Updated 2025-06-30)
Health Score
Price to Book Ratio (P/B)
-
Very Low
Low ≤ 1
High ≥ 3
Return on Equity (ROE)
-
High
Low ≤ 5%
High ≥ 25%
Return on Assets (ROA)
-
Very Low
Low ≤ 2%
High ≥ 10%
Free Cash Flow - Revenue % (FCF)
-
Very Low
Low ≤ 5%
High ≥ 15%
* Institutions hold a combined 0.00% of the total shares of AB Science S.A
* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.
Date
2026-03-31
EPS Estimate
—
Date
2017-12-31
EPS Actual
-0.39
EPS Estimate
—
EPS Difference
0
Surprise Percent
0%
(Last Updated 2025-06-30)
(Last Updated 2025-06-30)
Revenue
€ 0
Cost Of Revenue
€ 0
Gross Profit
€ 0
Operating Expenses
€ 0
Operating Income
€ 0
Interest Expense
€ 0
Pretax Income
€ 0
Net Income
€ 0
Income Tax Expense
€ 0
EBITDA
€ 0
Total Other Income Expense Net
€ 0
Earnings Per Share
0
Dividends Per Share
0
Shares Outstanding
0
Operating Margin
0%
(Last Updated 2025-06-30)
Cash
€ 0
Short Term Investments
€ 0
Receivables
€ 0
Inventories
€ 0
Total Current Assets
€ 0
Property Plant Equipment
€ 0
Total Assets
€ 0
Payables
€ 0
Short Term Debt
€ 0
Long Term Debt
€ 0
Total Liabilities
€ 0
Equity
€ 0
(Last Updated 2025-06-30)
Net Income
€ 0
Depreciation
€ 0
Change In Working Capital
€ 0
Cash From Operations
€ 0
Capital Expenditures
€ 0
Cash From Investing
€ 0
Cash From Financing
€ 0
Net Change In Cash
€ 0
Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.